IRLAB Therapeutics Q4 report: driving IRL757 development - ABG

Pirepemat topline data coming closer
IRL757 passes Ph 1 successfully
Webcast today at 10:00 CET


Events during the quarter

During the quarter, IRLAB initiated a second Ph 1 study with IRL757 in healthy elderly adults, which was completed and reported positive topline results on 31 January. IRLAB's most advanced project mesdopetam has received positive feedback from regulatory authorities to advance into Ph 3 and positive market research and a clinical data meta-analysis confirmed the drug candidate's potential for the treatment of Parkinson's levodopa-induced dyskinesia (PD-LIDs) (ABG note). After the reporting period - in January - IRLAB announced that the last patient in the pirepemat Ph 2b study (REACT-PD) has completed treatment, with the study being on track towards reporting of topline data. Also in January, the company has received a waiver from the EMA to test mesdopetam in children.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/irlab-therapeutics/Equity-research/2025/2/irlab-therapeutics---q4-report-driving-irl757-development/